<DOC>
	<DOCNO>NCT00773461</DOCNO>
	<brief_summary>This 2 arm study compare safety efficacy , regard reduction sign symptom , tocilizumab versus placebo , combination DMARDs , patient active rheumatoid arthritis currently inadequate response DMARD therapy . Patients randomize 2:1 receive tocilizumab 8mg/kg iv placebo iv every 4 week , conjunction stable DMARD therapy . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Tocilizumab Combination With DMARD Therapy Patients With Active Rheumatoid Arthritis .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>adult patient , 1870 year age ; rheumatoid arthritis &gt; = 6 month ; receive permit DMARDs , stable dose , &gt; = 8 week prior baseline ; current inadequate clinical response DMARDs . major surgery , include joint surgery , within 8 week enter study , plan major surgery within 6 month follow randomization ; rheumatic autoimmune disease inflammatory joint disease rheumatoid arthritis ; unsuccessful treatment antiTNF agent ; previous treatment tocilizumab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>